Cyclerion Therapeutics, Inc.
- CYCN
- NASDAQ
- Biotechnology
- CNS Drug Development
$23.52
Quote Sep 8, 2026, 08:00 PM UTC
+9.99%over the last month
Max drawdown −32.3%From 1-month high −17.4%3 months +30.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1
Founded
2018
Market value
$14.3M
Approximate share count
Floor
$23.22
1.3% below price
Resistance
$23.74
0.9% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CYCNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free